These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38455962)

  • 1. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.
    Zhu K; Chang Y; Zhao D; Guo A; Cao J; Wu C; Guan Y; Ding S
    Front Pharmacol; 2024; 15():1355081. PubMed ID: 38455962
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
    Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
    Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study.
    Wei Y; Zhang R; Yu C; Hong Z; Lin L; Li T; Chen J
    Front Pharmacol; 2023; 14():1230395. PubMed ID: 37645442
    [No Abstract]   [Full Text] [Related]  

  • 4. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).
    Wen F; Lin T; Zhang P; Shen Y
    Front Oncol; 2023; 13():1233196. PubMed ID: 38269021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
    Sheng X; Wang L; He Z; Shi Y; Luo H; Han W; Yao X; Shi B; Liu J; Hu C; Liu Z; Guo H; Yu G; Ji Z; Ying J; Ling Y; Yu S; Hu Y; Guo J; Fang J; Zhou A; Guo J
    J Clin Oncol; 2024 Apr; 42(12):1391-1402. PubMed ID: 37988648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
    Xu J; Zhang H; Zhang L; Chu X; Li Y; Li G; Nie C; Wang M; Guo Y
    Cancer Med; 2023 Dec; 12(23):21159-21171. PubMed ID: 37935113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
    Chen M; Yao K; Cao M; Liu H; Xue C; Qin T; Meng L; Zheng Z; Qin Z; Zhou F; Liu Z; Shi Y; An X
    Cancer Immunol Immunother; 2023 Jul; 72(7):2309-2318. PubMed ID: 36897337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial.
    Wang Y; Gong J; Wang A; Wei J; Peng Z; Wang X; Zhou J; Qi C; Liu D; Li J; Lu M; Lu Z; Cao Y; Yuan J; Zhang R; Fang J; Zhang X; Shen L
    EClinicalMedicine; 2024 Feb; 68():102415. PubMed ID: 38235421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review.
    Qi X; Guo J; Zhou X; Sun L; Lin J; Huang Z; Chen H; Lin L
    Heliyon; 2022 Sep; 8(9):e10581. PubMed ID: 36185140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study.
    Wang J; Liu Y; Zhang Q; Li W; Feng J; Wang X; Fang J; Han Y; Xu B
    Cancer Commun (Lond); 2024 Jul; 44(7):833-851. PubMed ID: 38940019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
    Nie C; Xu W; Guo Y; Gao X; Lv H; Chen B; Wang J; Liu Y; Zhao J; Wang S; He Y; Chen X
    BMC Cancer; 2023 Dec; 23(1):1239. PubMed ID: 38102538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population.
    Zhou L; Shao Z; Liu Y; Yan X; Li J; Wu X; Tang B; Li S; Cui C; Chi Z; Si L; Kong Y; Mao L; Lian B; Wang X; Bai X; Dai J; Guo J; Sheng X
    Oncologist; 2023 Aug; 28(8):e617-e624. PubMed ID: 36971495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
    Li T; Hu W; Jin L; Yin X; Kang D; Piao L
    Front Oncol; 2023; 13():1164368. PubMed ID: 37124509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer.
    Lei H; Ling Y; Yuan P; Yan X; Wang L; Shi Y; Yao X; Luo H; Shi B; Liu J; He Z; Yu G; Han W; Hu C; Chi Z; Cui C; Si L; Fang J; Guo J; Sheng X; Zhou A; Ying J
    J Natl Cancer Cent; 2023 Jun; 3(2):121-128. PubMed ID: 39035731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review.
    Lan Y; Zhao J; Zhao F; Li J; Li X
    Front Oncol; 2024; 14():1338661. PubMed ID: 38952555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
    Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
    Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.
    Zhao H; Xu Z; Li C; Xu T; Zhang J; Jiao J; Yang B; Qin R; Yang L; Qin W; Jing Y
    Adv Ther; 2024 Feb; 41(2):857-866. PubMed ID: 38048019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disitamab Vedotin: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1929-1935. PubMed ID: 34661865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma.
    Xu Z; Ma J; Chen T; Yang Y
    Front Immunol; 2022; 13():978266. PubMed ID: 36458005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.